NCT02365597
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 128 versions: 19 with changes below, 31 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Mar 31, 2027 to Dec 31, 2027
- Study sites revised (105)
- Notable Eligibility criteria expanded, about 12 words
- Secondary endpoints: details revised at 4 of 6 entries
- Study sites revised (105)
- Publications: details revised at 3 of 3 entries
- Minor Study completion date: Dec 31, 2026 to Mar 31, 2027v120
- Minor Study completion date: Oct 30, 2026 to Dec 31, 2026v117
- Minor Study completion date: Dec 31, 2025 to Oct 30, 2026v115
Show 14 earlier versionsHide 14 earlier versions
- Minor Study completion date: Dec 31, 2024 to Dec 31, 2025v106
- Minor Study completion date: Dec 29, 2023 to Dec 31, 2024v99
- Notable Results first posted: Oct 10, 2023
- Primary endpoints: 1 to 13
- Enrollment target: 243 to 239
- Secondary endpoints: 10 to 6
- Minor Enrollment target: 256 to 243
- Primary completion date: Sep 2022 to Sep 15, 2022
- Study completion date: Dec 2023 to Dec 29, 2023
- Start date: Apr 2015 to Apr 22, 2015
- Minor Enrollment target: 255 to 256
- Primary completion date: Sep 15, 2022 to Sep 2022
- Study completion date: Mar 31, 2023 to Dec 2023
- Start date: Apr 22, 2015 to Apr 2015
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 236 to confirmed 255
- Study sites: 161 to 105
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 255 to 236
- Study sites: 105 to 161
Notable Eligibility criteria revisedv87 Show 6 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 236 to confirmed 255
- Study sites: 161 to 105
- Primary completion date changed from estimate of Sep 27, 2022 to Sep 15, 2022
- Study completion date: Sep 27, 2022 to Mar 31, 2023
- Study description expanded, about 3 words
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 237 to 236
- Study sites: 105 to 161
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 236 to confirmed 237
- Study sites: 161 to 105
- Primary and study completion dates: Jun 30, 2022 to Sep 27, 2022
- Minor Site details revised at 2 of 161 sitesv83
- Minor Primary and study completion dates: Jun 2022 to Jun 30, 2022
- Start date: Apr 2015 to Apr 22, 2015
- Site details revised at 5 of 161 sites
- Minor Primary completion date: Jun 30, 2022 to Jun 2022
- Study completion date: Dec 31, 2023 to Jun 2022
- Start date: Apr 22, 2015 to Apr 2015
- Study sites revised (161)
- Minor Study sites: 160 to 161v79
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram \[mg\] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.
Drugs: Erdafitinib, Midazolam, Metformin
Sites
105 sites in 15 countries
United States 25, Germany 14, France 11, Spain 10, United Kingdom 7, Israel 6, Russia 6, Belgium 5, India 4, Romania 4, South Korea 4, Taiwan 4, Austria 3, Moldova 1, Turkey (Türkiye) 1